Skip to main content
. 2023 Jan 28;14:465. doi: 10.1038/s41467-023-36128-5

Fig. 6. Targeting specific GSL pathways suppresses PDAC tumors in vivo.

Fig. 6

a–f MIA PaCa-2 cells that stably express control vector (sgCtrl), or sgRNAs targeting UGCG, B4GALT5 (LCS), or ST3GAL5 (GM3S) were injected subcutaneously to opposing flanks of nude mice. Tumor size and volume (±SD, n = 8) of the MIA PaCa-2 xenografts were measured: a, b sgUGCG and control, c, d sgLCS and control, e, f sgGM3S and control. g, h Tumor size and volume (±SD, n = 8) of BxPC-3 cells stably expressing sgCtrl or sgGM3S in nude mice. a–h Differences from each cognate control were evaluated using t-tests (*p < 0.05). i–k Orthotopic implantation of control or UGCG-deleted KPC cells stably expressing luciferase to the pancreas of syngeneic mice. An in vivo imaging system (IVIS) was used to monitor the growth of the orthotopic tumors. i Representative images of luminescence signals of a mouse with control or knockout tumors at day 26 post-implantation. j Summary of luminescent activity of tumor burden 7–26 days post-implantation. Data are mean ± SEM. k Survival curves for mice with control or UGCG knockout tumors. n = 10 for each group. Differences between sgCtrl and sgUGCG were evaluated using two-tailed Student’s t-tests (*p < 0.05).